News

Under the licensing and development agreement, Pfizer will make an upfront payment to Avant of $40 million and will make a $10 million equity investment in Avant. Pfizer

This acquisition follows a development agreement, in place since June 2007, to pursue therapeutic solutions for atrial fibrillation, or ‘Afib’. The acquisition, which has been approved by the

The companies will ensure that patients enrolled in the ongoing Phase II study will continue to receive the current standard of care. ViroPharma also announced that ViroPharma and

Mr Pfeffer will report to Hakan Edstrom, president and COO, and will serve on MannKind’s executive leadership team. Mr Pfeffer’s appointment follows the previously announced retirement of Dick

As part of the collaboration, Xceed and the University of Florida will test approximately 700 samples from patients previously identified to have either cancerous or non-cancerous bladder tumors

In the completed dose-escalation Phase I/II trial, 72 patients with relapsed or refractory CD30-positive lymphoma received weekly doses of MDX-060 (0.1, 1, 4, 10 or 15mg/kg) for four

In this dose-escalating Phase I trial (trial 102), MGCD265 is administered orally to patients at an initial starting dose of 24mg/m2 daily on an intermittent basis (every other

Pursuant to the transaction, Metabasis reduced the exercise prices of the existing warrants held by the participants in exchange for the immediate exercise of the warrants. Metabasis also

Insmed’s INS-19, which is a recombinant form of human G-CSF, is a follow-on biologic of the FDA-approved product Neupogen. Preclinical studies demonstrate that INS-19 and FDA-approved Neupogen are